This study is for women with ovarian or peritoneal cancer. The purpose of the study is to see if we can lower the chance of ovarian or peritoneal cancer growing or spreading with a hormonal drug used either by itself or by adding it to the usual combination of chemotherapy drugs.
The purpose of this study is to determine at what dose the study drug (ASP1948) is safe and tolerated and how it is processed in the blood of patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study treatment causes tumors to shrink in patients.The screening period for this study can take up to 28 days. The treatment period consists of up to 48 weeks of initial treatment, followed by up to 45 weeks of follow up. If you quality and are willing to continue in the re-treatment period (receiving the study drug again), you will be in the study for an additional 48 weeks.
This study is for women who have ovarian cancer, fallopian tube cancer or primary peritoneal cancer which has grown or recurred. The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab. Atezolizumab is a PD-L1 inhibitor that may allow the immune system to recognize and destroy tumor cells.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.
The objectives of this trial are to find out whether adjuvant chemotherapy (using two other drugs) after chemo-radiation will increase the chances of survival and reduce the risk of tumor recurrence in the pelvis and other places. The risk and severity of side effects and quality of life during and after treatment will also be evaluated and compared. This trial will help the researchers understand the safety and effectiveness of this new treatment regimen for cervical cancer.